Cipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst ...

Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer ...

Bristol-Myers Squibb faces patent losses and growth headwinds despite pipeline gains, debt cuts, and dividends. Read why BMY ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the industry’s decline of 1.3%. The stock has also outperformed the sector in the ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...

By MELINDA J. OVERSTREET for Glasgow News 1 In September 2023, he had been fighting a cold for weeks and weeks. His immune ...

New Jersey-based Celgene said it is preparing a filing for Revlimid in combination with Roche’s rituximab, known as R 2, in patients with a slow-spreading form of lymphoma.

Revlimid has been backed for use as maintenance treatment for newly-diagnosed myeloma patients who are eligible for high-dose therapy and a stem cell transplant (HDT-SCT), who number around 1,400 ...

For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with or without high-dose therapy and autologous stem cell transplant (ASCT) -- ...

Bristol-Myers Squibb's rocky year didn't stop it from joining the Russell 3000 Growth Index, signaling long-term investor ...